This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Health Winners & Losers: Gilead

Health stocks closed the week on a relatively dull note, with light news and a few analyst tweaks.

The Nasdaq and Amex biotechnology indices were off 0.5% and by 0.6%, respectively, slightly worse off than the greater markets.

After the market closed Thursday, activist investor Carl Icahn continued his correspondence with Bristol-Myers Squibb (BMY - Get Report) CEO James Cornelius, the latest in their exchange regarding Bristol's rejected $60-a-share bid for ImClone Systems (IMCL). Icahn, who earlier in the week announced that a new bidder had offered $70 a share, said that should Bristol submit a new offer, he would respond accordingly.

ImClone shares closed down $1.13, or 1.7%, at $65.80, while Bristol traded up 41 cents, or 1.9%, to $22.23.

Elsewhere, Robert W. Baird analyst Thomas Russo upgraded Gilead Sciences (GILD) to outperform from neutral, noting that prescription trends suggest an in-line or better quarter shaping up. Also, Deutsche Bank analyst Mark Schoenebaum said in a note this week that the street could be underestimating the company's long-term profit margin potential.

Nonetheless, shares were off by 92 cents, or 1.9%, at $48.12.

A few analyst actions, RBC Capital Markets upped its price target for Micromet (MITI) to $8 from $4.50. The stock was up 75 cents, or 14%, at $6.07.

Also Jeffries and Co. upped its target for Allergan (AGN - Get Report) to $65 from $59. The stock was off by 79 cents, or 1.3%, at $59.74.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
IMCL $5.40 -3.57%
AGN $240.22 1.21%
BMY $65.76 0.77%
AAPL $126.37 2.53%
FB $83.20 -0.13%


DOW 17,976.31 +263.65 1.49%
S&P 500 2,086.24 +25.22 1.22%
NASDAQ 4,947.4410 +56.2220 1.15%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs